These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 17188882)
21. Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection. Stephenson D; Ramirez A; Long J; Barrezueta N; Hajos-Korcsok E; Matherne C; Gallagher D; Ryan A; Ochoa R; Menniti F; Yan J J Neurosci Methods; 2007 Jan; 159(2):291-9. PubMed ID: 16949674 [TBL] [Abstract][Full Text] [Related]
22. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease. Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351 [TBL] [Abstract][Full Text] [Related]
23. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Mogi M; Kondo T; Mizuno Y; Nagatsu T Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747 [TBL] [Abstract][Full Text] [Related]
24. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. Shin JY; Park HJ; Ahn YH; Lee PH J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187 [TBL] [Abstract][Full Text] [Related]
25. Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra. Yamamoto S; Fukae J; Mori H; Mizuno Y; Hattori N Neurosci Lett; 2006 Apr; 396(3):187-91. PubMed ID: 16386370 [TBL] [Abstract][Full Text] [Related]
28. Amiloride is neuroprotective in an MPTP model of Parkinson's disease. Arias RL; Sung ML; Vasylyev D; Zhang MY; Albinson K; Kubek K; Kagan N; Beyer C; Lin Q; Dwyer JM; Zaleska MM; Bowlby MR; Dunlop J; Monaghan M Neurobiol Dis; 2008 Sep; 31(3):334-41. PubMed ID: 18606547 [TBL] [Abstract][Full Text] [Related]
29. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Greffard S; Verny M; Bonnet AM; Beinis JY; Gallinari C; Meaume S; Piette F; Hauw JJ; Duyckaerts C Arch Neurol; 2006 Apr; 63(4):584-8. PubMed ID: 16606773 [TBL] [Abstract][Full Text] [Related]
30. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089 [TBL] [Abstract][Full Text] [Related]
31. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication. Rolland AS; Tandé D; Herrero MT; Luquin MR; Vazquez-Claverie M; Karachi C; Hirsch EC; François C J Neurochem; 2009 Aug; 110(4):1321-9. PubMed ID: 19527435 [TBL] [Abstract][Full Text] [Related]
32. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314 [TBL] [Abstract][Full Text] [Related]
33. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Liu LX; Chen WF; Xie JX; Wong MS Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104 [TBL] [Abstract][Full Text] [Related]
34. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. Hunter RL; Dragicevic N; Seifert K; Choi DY; Liu M; Kim HC; Cass WA; Sullivan PG; Bing G J Neurochem; 2007 Mar; 100(5):1375-86. PubMed ID: 17254027 [TBL] [Abstract][Full Text] [Related]
35. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats. Rojo AI; Cavada C; de Sagarra MR; Cuadrado A Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941 [TBL] [Abstract][Full Text] [Related]
36. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. Anderson DW; Bradbury KA; Schneider JS Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732 [TBL] [Abstract][Full Text] [Related]
37. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy. van Vliet SA; Blezer EL; Jongsma MJ; Vanwersch RA; Olivier B; Philippens IH Brain Res; 2008 Jan; 1189():219-28. PubMed ID: 18076869 [TBL] [Abstract][Full Text] [Related]
38. Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice. Chertoff M; Di Paolo N; Schoeneberg A; Depino A; Ferrari C; Wurst W; Pfizenmaier K; Eisel U; Pitossi F Exp Neurol; 2011 Feb; 227(2):237-51. PubMed ID: 21093436 [TBL] [Abstract][Full Text] [Related]
39. Influence of age and gender on cytokine expression in a murine model of Parkinson's disease. Ciesielska A; Joniec I; Kurkowska-Jastrzebska I; Przybyłkowski A; Gromadzka G; Członkowska A; Członkowski A Neuroimmunomodulation; 2007; 14(5):255-65. PubMed ID: 18196934 [TBL] [Abstract][Full Text] [Related]
40. Neuroprotective effects of enriched environment in MPTP-treated SAMP8 mice. Yuan ZY; Gu P; Liu L; Wang YY; Liu J; Cui DS; Geng Y; Zhang ZX; Zhu AP; Ma L; Wang MW Neurosci Lett; 2009 Apr; 454(1):6-10. PubMed ID: 19429044 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]